secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scilex Holding Co (SCLX)
CIK:        0001820190
Form:       8-K
Filed at:   2023-03-21T23:59:59+00:00
Accession:  0001193125-23-075731
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scilex enters $25M convertible debenture financing with Yorkville for pain product launch
--------------------------------------------------------------------------------

- Up to $25M in convertible debentures issued in three tranches: $10M funded, $7.5M upon SEC filing, $7.5M upon effectiveness.
- 7.00% annual interest, matures Dec. 21, 2023; conversion at $8.00/share subject to one-time VWAP reset after 60 days.
- Proceeds to boost commercialization of ZTlido, Gloperba, and ELYXYB for non-opioid pain management.
- Conversion capped at 4.99% beneficial ownership (waivable) and 19.9% of outstanding shares unless stockholder approval obtained.
- Registration rights granted for resale of underlying common shares; first $10M tranche closed simultaneously.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1820190/000119312523075731/0001193125-23-075731-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1820190/000119312523075731/d280460d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-075731

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer